logo
  Join        Login             Stock Quote

Ambit Biosciences Files For IPO Of Up To $58M

 February 21, 2013 01:25 PM
 


(By Balachander) Ambit Biosciences Corp., a kinase drug development company, has filed to raise up to $58 million in an initial public offering (IPO) of common stock.

The filing with the U.S. federal regulators did not disclose how many shares the company plans to offer or the pricing terms.

The  San Diego, California-based biopharmaceutical company withdrew its $86 million IPO in 2010.

Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) a validated target in the treatment of acute myeloid leukemia (AML).

Quizartinib is currently in Phase 2b clinical development in patients with relapsed/refractory AML who express a genetic mutation in FLT3.

[Related -Invest In Stocks With A Margin Of Safety To Reduce Risk And Enhance Returns]

The company has partnered with Astellas Pharma Inc. for the worldwide co-development and commercialization of quizartinib.

Ambit plans to use the net proceeds from the offering and the concurrent private placement to fund the continued clinical development of quizartinib, its other programs and for working capital and other general corporate purposes.

The company's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd (TEVA).

For the year ended 2012, the company posted a net loss attributable to Ambit of $26.65 million.

[Related -Teva Pharmaceutical (TEVA) Dividend Stock Analysis]

Ambit intends to list on the NASDAQ under the symbol "AMBT."

Ambit said certain of its existing stockholders have agreed to purchase shares of Ambit's common stock in a separate private placement concurrent with the completion of the offering at a price per share equal to the initial public offering price.

Citigroup and Leerink Swann are the joint bookrunners of the offering.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageRussell 2000 Showing Relative Weakness at the New Highs

A quick “Quad Index” Grid shows us that the small-cap Russell 2000 is showing relative strength to the read on...

article imageThe Poster Boy For Liberal Economics Discovers The Tax Factor

Paul Krugman seems to be having a supply-side-economics moment… sort of. Raising taxes, the NY Times read on...

article imageMacroprudential Policy And Distribution Of Risk

There is very little doubt that housing prices and leverage played a strong role in the global financial read on...

article imageIs the World Turning Japanese?

Many really think so, but reality suggests read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.